Please fill all fields and submit the form.





Please fill out all fields in the form. Please be as detailed as possible. We will respond with pricing and availability within 1-2 business days.




Organ/Tissue type:


Number of patients/donors required for the study:

Clinical Specifications:

Applications/Research topic:

ERCC1 Gene Expression Analysis Kit

  • Cat.-#: CMD-ER24
    Unit Size: kit (24 tests)

ERCC1 Gene Expression Analysis Kit Description

The ERCC1 test provides information about the potential sensitivity of a patient's cancer to platinum-based therapies.

The combination of carboplatin and paclitaxel is the most commonly used regimen for the treatment of advanced non-small cell lung cancer (NSCLC) patients. These drugs inhibit cancer growth by damaging DNA. The expression of the DNA-repair gene excision repair cross-complementation group 1 (ERCC1) is reported to be correlated with resistance to platinum-based drugs. Tumor cells with low ERCC1 enzyme may be more sensitive to platinum-based drugs since they are less able to repair damaged DNA. Results from several clinical studies suggest that a low level of ERCC1 gene expression is a good biomarker for clinical sensitivity to cisplatin, carboplatin, and oxaliplatin. In the IALT Bio study, patients who had non-small cell lung cancer with no detectable ERCC1 had longer disease-free survival after cisplatin-based chemotherapy than did patients with a tumor that contained ERCC1 (P<0.001) [1]. In a study of ERCC1 gene expression as a prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy, median survival was significantly higher in patients with low ERCC1 levels (25.4 versus 15.4 months; P = 0.03) [2]. And a retrospective study by Ceppi et al of NSCLC found that patients treated with platinum who had low ERCC1 mRNA in their tumors had significantly longer survival than patients with high ERCC1 expression (median survival 14.9 versus 9.9, p = 0.012) [3].

1. Olaussen KA, Dunant A, Fouret P, Brambilla E, André F, Haddad V et al. (2006). DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 355 (10): 983-91.
2. Bellmunt, et al. (2007) Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy. Ann Oncol. 2007 Mar;18(3):522-8.
3. Ceppi, et al. (2008) Excision repair cross complementing-1 and topoisomerase IIalpha gene expression in small-cell lung cancer patients treated with platinum and etoposide: a retrospective study. J Thorac Oncol. 2008 Jun;3(6):583-9.